Viking Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 1st, 2016 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Viking Therapeutics, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share ( “Common Stock”) and warrants to purchase an aggregate of shares of Common Stock (the “Warrants,” and collectively with the Firm Shares, the “Firm Securities”). In addition, the Company proposes to grant to the Underwriters an option to purchase from the Company up to an additional shares of Common Stock (the “Option Shares”) and/or Warrants to purchase up to an additional shares of Common Stock (the “Option Warrants”) for the purpose of covering over-allotments in connection with the sale of the F
WARRANT AGREEMENTWarrant Agreement • April 1st, 2016 • Viking Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2016, is by and between Viking Therapeutics, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as the Warrant Agent (the “Warrant Agent”).
